Meta-analysis of 5 RCTs (n=1912) in atopic dermatitis: ruxolitinib cream vs vehicle improved treatment success on the Investigator's Global Assessment at 8 weeks (RR 4.00) and EASI75 (RR 3.16), with similar adverse event risk.
Meta-analysisn = 1,912
Ghanem et al. Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta-analysis